This interactive publication was created by InvestorBrandNetwork With over a decade of experience assisting 500+ client partners improve communications within the investment community and a sizable family of 50+ trusted brands, IBN has amassed a collective audience that includes millions of social media followers. IBN is committed to leveraging the scale of this audience, as well as the knowledge and experienced gained through the years, to best serve an increasingly diversified list of client partners. Through its portfolio of complementary brands, IBN provides (1) access to our network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release solutions so to ensure maximum impact, (4) full-scale distribution to a huge social media audience, (5) a full array of corporate communications focused on the IBN Podcast Series. IBN is a multifaceted organization with an extensive team of contributing journalists and writers. IBN is uniquely positioned to serve private and public companies aiming to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market and cultivating strategic partnerships with leaders from multiple industries, IBN brings our client partners unparalleled visibility, recognition and focus with optional solutions like Brand Awareness Distribution (BAD) and our InvestorOutreachCenter (IOC).
FEBRUARY 2022 FLORAGROWTH.COM NASDAQ FLGC Investor Presentation.
2 FLORA GROWTH S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L This presentation contains reference to certain intentions, expectations, future plans, strategies and prospects of Flora Growth Corp. (“Flora”), which may constitute forward looking information under applicable securities law, including within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this presentation, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward looking statements. Those intentions, expectations, future plans, strategies and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of Flora may be influenced by a number of factors, many of which are outside the control of Flora. No representation or warranty, express or implied, is made by Flora, or any of its shareholders, directors, officers, advisers, agents or employees that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause Flora’s actual future results, performance or achievements to be materially different from those expected, planned or intended, you should not place undue reliance on these intentions, expectations, future plans, strategies and prospects. Flora does not represent or warrant that the actual results, performance or achievements will be as intended, expected or planned. All information contained in this presentation is provided as of the date of the presentation and is subject to change without notice. Neither Flora, nor any other person undertakes any obligation to update or revise any of the forward looking statements set out herein, whether as a result of new information, future events or otherwise, except as required by law. This presentation shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities of Flora in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This is presented as a source of information and not an investment recommendation. Some of the factors that could cause actual results to differ materially from those expressed or implied by the forward looking statements in this presentation include but are not limited to: • Our limited operating history and net losses • Unpredictable events, such as the COVID-19 outbreak, and associated business disruptions • Changes in cannabis laws, regulations and guidelines • Decrease in demand for cannabis and derivative products due to certain research findings, proceedings, or negative media attention • Damage to our reputation as a result of negative publicity • Exposure to product liability claims, actions and litigation • Risks associated with product recalls • Product viability • Continuing research and development efforts to respond to technological and regulatory changes • Shelf life of inventory • Maintenance of effective quality control systems • Changes to energy prices and supply • Risks associated with expansion into new jurisdictions • Regulatory compliance risks • Opposition to the cannabinoid industry • Risks related to our operations in Colombia • Potential delisting resulting in reduced liquidity of our Common Shares. This presentation contains or references certain market, industry and peer group data which is based upon information from independent industry publications, market research, analyst reports and surveys and other publicly available sources. Although Flora believes these sources to be generally reliable, such information is subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other inherent limitations and uncertainties. Market research and public data. Forward-looking information.
4 FLORA GROWTH S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L The Opportunity. Empower consumers. Motivated by philosophies rooted in thinking differently, what we deliver continues to change how consumers think and how they value experiences. Design experiences. We focus tirelessly on the intangibles of every human experience and how people connect with what we create, while maintaining the discipline of operational excellence in all that we do. Welcome collaboration. We’re drawn to the hard work and opportunities to collaborate with those who share the same principles. The Problem. Narrow focus. The arrival of cannabis and hemp signals a generational opportunity to accelerate a paradigm shift, moving “alternative” plant-based wellness solutions and lifestyle products into mainstream. Commodity offering. Consumers are receptive, but they’re lost and confused. They’re starving for leadership and clear direction. They want better, more considered experiences but many are too heavily focused on commodity cannabis and cannabinoid-based products and missing a much larger opportunity. Fragmented. Inexperienced teams have significant challenges learning how to manage goto-market and global supply chains, hindering true value creation. The market is fragmented with no one truly delivering an ecosystem of product experiences led by thoughtful design. PROBLEM + OPPORTUNITY
5 FLORA GROWTH S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L Our mission is to build a design-led collective of plant-based wellness and lifestyle brands that delivers the most compelling customer experiences in the world, one community at a time. OUR MISSION
6 FLORA GROWTH S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L Investment Highlights. Exceptional Leadership. P E O P L E Former Macy’s executives and cannabis / CPG / capital markets experience, with $3B+ raised in public financings. Global House of Brands. B R A N D S Over 340+ products and 70+ medical, cosmetic licenses, and 2,500+ points of distribution across LATAM and U.S. with sales across 13 other countries. Disciplined M&A Pipeline. A C Q U I S I T I O N S Strategic targets identified with near term revenue growth and global distribution channels. Targeting category leaders and disruptors. High-Revenue Growth. G R O W T H Well-positioned with launch of new operating divisions and healthy balance sheet after two successful financings. Global Expansion. E X P A N S I O N Completing international acquisitions and investments focused on brands and distribution. Multiple cannabis sales LOIs signed. Low-Cost Cultivation. S U P P L Y C H A I N All natural, outdoor cultivation with production costs +/- US $0.06 per gram; 60% lower than next closest peer. INVESTMENT HIGHLIGHTS
7 FLORA GROWTH S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L Focus on Our People. Brand builders. Led by a proven team that shares decades of industry-leading experience building CPG brands and managing global ecommerce, retail and distribution. Disciplined operators. Track record as disciplined operators and category disruptors with an emphasis on building direct-to-consumer brands and loyal communities. Track record. Combined with the team’s track record commercializing hundreds of consumer goods through a vast and diverse global supply chain, Flora is building what many have promised, yet few have delivered. Why we’re different. LEADERSHIP & PEOPLE It begins with people. Lead by design. Build community. P E O P L E D E S I G N C O M M U N I T Y Everything is possible with the right people. People have been the key to our strategy and execution for decades - it doesn’t change here. Attracting and recruiting contrarian thinkers in each of our key verticals will allow us to remain innovative, move assertively with speed of execution, and build a culture that stands alone. Creating customer experiences they will talk about is where many struggle today. Product design, assortment, UX, packaging, social and environmental thoughtfulness - the ability to bring this all together motivates people to engage and experience what we have to offer. We build our team, we use design to lead the industry, all for who? Community. We are a customer-first organization focused not only on designing remarkable experiences but including them in our journey to do things differently - the right way.
8 FLORA GROWTH S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L Meet a Few Members of Leadership. Luis Merchan President & CEO Jason Warnock Chief Revenue Officer Jessie Casner VP of Marketing - Vessel James Williams VP of Corporate Development James Choe Founder/CEO - Vessel Mr. Merchan is a proven executive with over 10 years of experience in enterprise sales management, corporate strategy, merchandising and expense management and customer experience. He previously served as Vice President of Workforce Strategy and Operations for Macy’s Inc. where he managed the enterprise’s P&L expense line for its 540-store portfolio. Throughout his tenure at Macy’s, prior to his most recent role, Mr. Merchan held various executive-level roles at Macy’s as well as managerial roles at Target. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogotá, Colombia and his MBA from McNeese State University. Mr. Merchan also holds a Graduate Certificate in Marketing Management from Harvard University. Mr. Warnock is an accomplished global sales leader and executive, bringing more than 20 years of experience driving revenue growth and go-to-market strategy for high-profile, Fortune 500 brands. Mr. Warnock has spent the last 15 years in the cannabis, competitive advertising, communications, and emerging technology fields where his work focused on building companies and brands from the ground up, working on M&A, and creating sustainable, resonant financing and marketing campaigns. Prior to joining Flora, Mr. Warnock was the CEO of TheraCann International. Before TheraCann, he was the CEO of Post+Beam, an international communications, innovation and marketing firm. He is experienced in delivering consistent results for numerous CPG companies and developing high-performing teams and effective marketing communications. Jessie Casner is the Vice President of Marketing for Vessel Brand and a San Diego native. An experienced omnichannel marketer and storyteller, Casner previously operated her own agency, Junction Marketing, where she developed and executed bespoke go-to- market strategies. An early team member of The Active Network during its rapid growth phase (pre-IPO and acquisition), MOGL (now EMPYR, during series A/B funding), 2XU, and Total Gym, Casner brings a strong knowledge and background in the startup, sports and apparel industries. Casner wears many hats in her role with the company, managing tactics for its direct-to-consumer business, product development and timelines, and optimizing the customer experience. More broadly, she works closely with CEO of Vessel, James Choe on their brand messaging and content, strategic partnerships, new avenues for growth, and podcast, Vessel Sessions. Mr. Williams is a corporate finance and business development specialist who has spent the previous three years focused on driving corporate M&A and revenue opportunities within the regulated cannabis industry. Most recently, Mr. Williams was the Founder of Cannabis Manufacturers Guild in early 2020, a business solutions trade association for the cannabis space. Prior to that, he worked with WeedMD Rx as Director of Capital Markets and Business Development focusing on capital raising and M&A analysis. Before entering the corporate cannabis space, Mr. Williams specialized in cannabis securities at Laurentian Bank and has worked in investment banking for 10 years including time at Barclays Securities and UBS Investment Bank. Mr. Williams graduated with a BBA from Wilfrid Laurier University, with a Minor in Economics. James Choe is the Founder/CEO of Vessel, the leading brand in cannabis consumption technology with its luxury vape and dry herb accessories. Choe got his first taste of startups in 1999 with broadband pioneer Softnet Systems in Mountain View, CA. After building the business to prominence and growing to more than 300 employees, Choe left to pursue his heart’s passion – a career in the sports industry where he would represent athletes in the Olympics, NFL, MLB, NHL, Lacrosse and Action Sports for over 12 years. From 2010-2014, Choe led as VP of Sports/Retail Marketing at SKLZ, the global leader in sports training products, partnering with several of the world’s largest retailers including Walmart, Dick’s Sporting Goods and Sports Authority. Throughout his 20 year career, Choe has mentored and consulted over 100 brands to date, while he has also led the design, development and successful launch of more than 400 products across nearly all CPG categories. Originally from Saratoga, CA, Choe graduated from San Diego State University. LEADERSHIP & PEOPLE
9 FLORA GROWTH S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L Meet Our Board of Directors. Advisory Board. Bernard Wilson Chairman Mr. Wilson is a senior financial professional. He is the former Vice-Chairman of PriceWaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. Mr. Wilson has served as Chairman of the Canadian Chamber of Commerce, Chairman of the International Chamber of Commerce - Canada; and Member of the Canada/US Trade Committee. Drawing on his experience, Mr. Wilson will work with the Board of Directors of Flora and its various standing committees to ensure effective corporate governance practices and to enhance and protect the independence of the board. Juan Carlos Gomez Director Mr. Gomez is a proven business leader with over 30 years of professional experience working for multinational public companies. He brings substantial experience in the Latin American market, across a variety of business competencies including business operations, M&A, business integration and corporate governance. For the past 20 years, Mr. Gomez served as the COO, and eventually as CEO of the Winner Group, CIRSA, owned by the Blackstone Group, where he was responsible for growing the company to become one of the largest 100 companies in the country through meaningful organic and M&A driven growth initiatives. This included expansion across 28 cities and more than 2,800 staff. Mr. Gomez obtained his bachelor’s degree in Organizational Psychology from the University of Santo Tomas in Colombia. Tim Leslie Chairman of the Advisory Board A Yale law graduate, Leslie has a strong pedigree of success, working with scaling companies including his two decades at Amazon, where he served as Vice President and Associate General Counsel responsible for building and managing Amazon’s international legal team before changing roles to oversee the international launch of Amazon Prime Video. Following his successful tenure at Amazon, Leslie made the leap to the burgeoning cannabis industry where he served as CEO of one of the world’s most authoritative digital cannabis data sources, Leafly. Since his time there, Leslie has served on the board of renowned cannabis companies before his appointment as Chairman of the Board of Advisors at Flora. Marc Mastronardi Director Marc Mastronardi is a seasoned executive and current Chief of Stores of Macy’s. Prior to his current role, Mastronardi was Macy’s Senior VP of Store Operations and Customer Experience, where he was responsible for enterprise-wide store operations, sales, and customer service. Mastronardi has also led multiple functions within the organization, responsible for the creation and expansion of new business concepts, leased partnerships and diverse owner-led businesses. Mastronardi currently serves on the board of Delivering Good, NYC, the executive committee of the Fashion Scholarship Fund, and is the executive sponsor of the Macy’s Working Families Employee Resource Group. Dr. Annabelle Manalo-Morgan Director Luis Merchan President & CEO / Director Dr. Annabelle is a scientist, educator, author, mother of five and a respected key opinion leader. She is a cell and developmental biologist from Vanderbilt University with a background in neuroscience from Georgetown University. She earned her Ph.D. in Cell and Development Biology with a focus in Cardio-Oncology and has since become a philanthropist and entrepreneur focused on pharmaceutical innovation and clinical trial research in medical cannabis. Bio on Page 9. Dr. Beverley Richardson Director Dr. Beverley J. Richardson is a renowned psychotherapeutic practitioner whose collaborative efforts and clinical influence are reflected in some of the most compelling and effective addiction and behavioural health programs in North America which include: Sierra Tucson (Arizona), the Meadows (Arizona) and Betty Ford Centre (California). She has a Doctorate Degree in Psychology and is a B.C. Registered Clinical Counsellor, Internationally Certified Eating Disorder Specialist, and EMDR Level II Trauma Therapist. Dr. Richardson has integrated her extensive experience in health and wellness with her entrepreneurial spirit to form her nutraceutical and bioscience research and development enterprises. LEADERSHIP & PEOPLE
10 FLORA GROWTH S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L Flora Growth Applauds Update to Colombian Cannabis Regulations. The new regulations are expected to allow Flora to increase near-term and long-term revenue, where the following points highlight the impact of this legislative change. Flora has signed two agreements to supply cannabis flower and derivatives to Australian and South African distributors since this law was signed. GLOBAL EXPANSION Custom Formulas. Marketing Capabilities. Dried Flower. P E R M I T T E D Cannabis Ingestibles. P E R M I T T E D P E R M I T T E D I M P R O V E D The sale of dried cannabis flower, where dried flower accounts for over 50% of the sales demand in the global cannabis market, positions Colombia’s cultivators as global supply leaders. The manufacturing, sale and export of cannabinoid ingestible products, benefiting Flora’s food and beverage division, which recently signed a $10M distribution agreement. By permitting cannabinoid medical products through drugstores as “custom formulas”, access to cannabis products is substantially increased within the domestic Colombian market. Cannabis marketing restrictions removed, allowing Flora to drive increased awareness across its portfolio of products and driving additional sales through its 1,500+ points of distribution within Colombia.
11 FLORA GROWTH S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L • Made initial equity investment of €2M (two-million Euros) into Hoshi International • Investment will establish Flora as a preferred strategic supplier to Hoshi’s two EU processing facilities, located in Malta and Portugal, expected to be operational in 2022 • Opens distribution gateway of Flora’s Colombian cannabis and product portfolio into the European Union • Hoshi’s experienced team and access to major cannabis markets to serve as a catalyst for revenue growth • Flora to leverage various international distribution agreements throughout the European Union, including the United Kingdom, Germany, and Poland Furthering our expansion in Europe with manufacturing and distribution. • Flora’s Food & Beverage division, Kasa Wholefoods signed an initial 1-year sales agreement expected to be worth over US $10M to supply food products to Tropi • Tropi is Colombia’s largest food distributor and reaches over 130,000 distribution points across 38 cities in Colombia. • Kasa Wholefoods completed first delivery in July 2021 worth US $1.1M under agreement, expects sales to reach approximately US $2M per month. • Kasa expects to generate additional sales of its entire food and beverage product portfolio, including its portfolio of cannabinoid containing ingestible products given recent law change. Growing distribution channels and sales relationships with major CPG distributors. Expanding Global Distribution. • Formed JV with Avaria for the sale of its award winning KaLaya brand across LATAM. • Flora to support the development and production of CBD pain cream formulations for the global market, with an immediate focus on export to LATAM and the U.S. • Profits from the sale of KaLaya products divided equally, with Flora managing distribution, increasing the value of Flora’s existing 2,500+ distribution channels • KaLaya has sold 1M+ units across Canada through major retailers (Loblaws, Walmart, London Drugs), and holds the number one customer retention rate of Loblaws’ pain creams, among other awards (TSC, Amazon.ca’s Consumer Choice, Purity Life). Increasing value of Colombian distribution through JV with established brand. GLOBAL EXPANSION E U R O P E C O L O M B I A L A T I N A M E R I C A
12 FLORA GROWTH S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L • Completed the acquisition for 100% of Vessel Brand, Inc. for aggregate cash and share consideration of US $30M • Vessel posted trailing twelve-month revenues of US $6.6M and 90% year-over-year growth (unaudited) • The acquisition expands and diversifies its global distribution channels by adding industry leader in luxury cannabis consumer technology segment • Strengthens Flora’s executive bench by adding key human capital in the areas of brand, design, product, marketing and sales • Enhances consumer packaged goods presence and infrastructure in the U.S. with widespread distribution throughout North America and various international markets utilizing the team’s e-commerce expertise Consumer Technology. Completed acquisition of Industry Leader in Luxury Cannabis Consumer Technology. ACQUISITIONS / HOUSE OF BRANDS T E C H N O L O G Y
13 FLORA GROWTH S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L L E G E N D Food & Beverage. B R A N D S KASA WHOLEFOODS MAMBE ALMOST VIRGIN Cannabis & Hemp. S U P P L Y & T R A D E COSECHEMOS FLORA LAB S.A.S Ancillary & Technology. T E C H N O L O G Y DRY HERB V E S S E L VAPE DTC & B2B Lifestyle & Apparel. B R A N D S STARDOG HEMP TEXTILES & CO. Skincare & Cosmetics. B R A N D S FLORA BEAUTY MIND NATURALS Ô Nutraceuticals & Wellness. R E S E A R C H & I P FLORA PHARMA KALAYA CARDIFF MUNZHI We’re building an ecosystem that will support market-leading innovation within categories that matter most to consumers exploring plant-based consumer goods. We have the team, go-to-market leadership and playbook, brand expertise, research and technology, supply chain, and confidence to continue to deliver remarkable customer experiences and do it more efficiently and more assertively than our competitors. BRANDS SIGNED LOI ASSETS HOUSE OF BRANDS / M&A TONINO LAMBORGHINI
14 FLORA GROWTH S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L Kasa Wholefoods. Kasa Wholefoods, a division of Flora, produces food and beverages (Mambe) using responsibly sourced exotic fruits from the Amazon. Mambe’s brand ambassador is Laura Londoño, the awardwinning Latin-American actress with a strong following of 1.3M+ on Instagram. Distribution via Tropi Supply food products to Colombia’s largest food distributor, Tropi, which has 130,000+ distribution points across Colombia. Kasa expects to generate additional sales of its CBD and hemp portfolio and expects sales to reach ~US $2M /mo. Flora Growth has the sole and exclusive license agreement with Tonino Lamborghini S.P.A. for the manufacturing, promotion and distribution of Tonino Lamborghini branded beverages using Cannabidiol (“CBD”) and Cannabigerol (“CBG”) for North America and Colombia. The Q1 2022 launch will include cold coffee drinks, vitamin waters and fresh juices. Flora Growth also retains the right of first refusal on any or all additional Tonino Lamborghini products containing cannabinoids for the territory which may include, but not limited to; beverages, edibles, wellness or other ingestibles and for the expansion or addition of new geographic regions or territories. HOUSE OF BRANDS
15 FLORA GROWTH S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L Flora Beauty. Flora Beauty is the CBD beauty and cosmetics division of Flora Growth. Distribution • E-commerce across the U.S. and Colombia • Launched sales on Walmart.com and Coppel in Mexico • Completed initial shipment into the UK and Spain, exploring opportunities in other European markets • Sold through Falabella’s 111 retail locations across Latin America Sustainability Received industry recognition (Cosmoprof North America) for innovative sustainable packaging. HOUSE OF BRANDS Flora Beauty’s two CBD skincare brands target the United States and Latin American markets.
16 FLORA GROWTH S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L Hemp Textiles & Co. The Hemp Textiles division will leverage Flora Growth’s large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials market segment Distribution • E-commerce: Zulily (US), Website (Global) • Brick and mortar: Bogotá and Miami • Launched on Macys.com Noteworthy • Natural, antibacterial and sustainable • Highly-durable and suitable for multiple frontline textile industries (military, medical, hospitality, tourism, etc.) • Secondary products: bioplastics, paper, hempcrete, skincare and hair products HOUSE OF BRANDS A V A I L A B L E A T Stardog Loungewear. Stardog Loungewear is a comfortable loungewear made from natural, organic materials. A SUPERIOR FIBER HEMP
17 FLORA GROWTH S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L High-Quality Manufacturing. Flora Lab is the manufacturing and R&D centre that produces pharmaceuticals, cosmetics, nutraceuticals for domestic and international markets. Includes product lines that are private label, white label, and custom formulations. Track record of success. • Currently manufacturing and distributing 63+ OTC products registered with INVIMA 1 • Selling across 2,500+ distribution channels • Breeze pursuing “custom formula” certification to produce cannabinoid containing medications Certified manufacturing. • Underpinned by 16,000 sq. ft. facility with modern laboratory • Flora Growth holds 3 GMP certifications: + Cosmetics + Phytotherapeutics + Dietary Supplements • The laboratory has the capability to produce wide range of CBD-enhanced products RESEARCH & IP 1 INVIMA - Colombia National Food and Drug Surveillance Institute (FDA equivalent in Colombia) R E S E A R C H & D E V E L O P M E N T
18 FLORA GROWTH S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L Research. Helmed by Director and Lead Scientific Advisor, Dr. Annabel Manolo-Morgan, PhD, Flora’s research arm seeks to support leading scientists and research institutions such as Vanderbilt University and the University of Manchester to advance access to and research of cannabinoid-based medicine. Delivery. Flora Pharma is ground zero for product innovation. Creating and building upon novel delivery modalities that provide the best consumer experience is core to Flora’s mission. Efficacy. Flora Pharma looks to identify the most efficacious combination of plant-based compounds and derivatives to provide consumers with products that satisfy the commitment to better living through thoughtful and curated wellness products. RESEARCH & IP S C I E N T I F I C R E S E A R C H & I N N O V A T I O N D I V I S I O N
19 FLORA GROWTH S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L Location is our advantage. S U P P L Y C H A I N INFRASTRUCTURE BUCARAMANGA, COLOMBIA Climate. 12+ hour days, 3-mph winds 365 days a year Location. Slopes of Bucaramanga 3,000+ feet above sea level, deep agricultural history Natural resources. Sunlight, natural spring water deposits, and nutrient-dense soil
20 FLORA GROWTH S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L Cultivation Success. 2021 Colombian export quota. Received 2021 commercial export quota for cultivation of ~7,900 kg of high-THC cannabis flower from Colombian government. Signed letters of intent to distribute cannabis flower and derivatives with distributors in Australia and South Africa. Demonstrating impressive results. • Production cost of < US $0.06/gram • Yield of 125+ grams/plant • Initiated third-party organic and GACP certification Value opportunity The Cosechemos cultivation farm, located in Bucaramanga, Colombia, is licensed to cultivate 247 acres (100 hectares) of cannabis. Cosechemos is harvesting high-CBD strains of cannabis, while simultaneously preparing for commercial production of high-THC. INFRASTRUCTURE Extraction facility complete. Seed-to-sale traceability. A S S E T T E C H N O L O G Y Cosechemos, has produced the first batch of crude oil through its newly constructed extraction facility. Further, Cosechemos has initiated the process to become EU-GMP certified. Launching differentiated global cannabis product validation and authentication platform for consumers, distributors, and government regulators that offers forensic level seed-to-sale traceability. S U P P L Y C H A I N
21 FLORA GROWTH S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L Low-cost Colombian Cannabis Cultivation. Favorable growing conditions. • Developing unique organic agronomic management system tailored to Cosechemos’ climate and conditions • Consistent 3-mph wind decreases incidence of plant-harming pathogens due to winds and access to other vegetation • Organic nutrient-rich soil allows for high-density planting • Optimized cultivation strategy to obtain 3+ harvests per year (1.5-3X more than peers) Experienced and affordable labor. • Low-cost without compromising quality; over 70% of all cut flowers imported to U.S. come from Colombia • A strong U.S. dollar provides Flora with a cost advantage; US $1 = ~3,884.84 pesos 1 • Colombia has a highly-skilled workforce in agriculture at only 1/10th of the cost compared to the United States 2 $1.49 $0.15 $0.06 $1.85 $1.86 $2.36 INFRASTRUCTURE S U P P L Y C H A I N 1 https://www.bloomberg.com/quote/USDCOP:CUR (11/14/21) | 2 https://mjbizmagazine.com/great-cultivation-debate (5/2017) SOURCE: Each company’s filings and presentations (FY 2019) $ 10 /acre < $ 150 $ 0 Long-term monthly lease w/ purchase option Monthly utility costs Water cost due to natural deposits SUNLIGHT / DAY CONSTANT WIND DAYS / YEAR 12.8H 3MPH 365 FLORA USD/GRAM OTHER LPs USD/GRAM $0.06 $1.49-2.36 VS Flora’s Cost Advantage. LOWER COST THAN CLOSEST COMPETITOR 60%
22 FLORA GROWTH S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L Cost to Grow 1/8th (3.5g) of Flower Cost to Grow 1/8th (3.5g) of Flower A closer look with a target of 80% gross margins. COGS COGS Includes Processing, Packaging, Fulfillment Includes Processing, Packaging, Fulfillment 80% GM MULTIPLIER 80% GM MULTIPLIER SUGGESTED RETAIL PRICE SUGGESTED RETAIL PRICE $0.21 5X 5X $2.50 $2.50 $2.71 $13.55 $45.75 $9.65 $6.65 Flora Growth Avg of LPs Cost Comparison to Grow and Sell 1/8th (3.5g) of Dry Flower. S U P P L Y C H A I N F O R I L L U S T R A T I V E P U R P O S E S O N L Y INFRASTRUCTURE
23 FLORA GROWTH S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L Exceptional Land Package. Large scale Cosechemos’ 10.8 million square feet (247 acres) of licensed cultivation area can make Flora Growth a substantial cultivator in the cannabis industry. INFRASTRUCTURE S U P P L Y C H A I N Flora Growth 0.0 1.5 3.0 Cultivation Footprint (M sq ft) 4.5 6.0 Aphria Clever Leaves Aurora PharmaCielo Hexo Organigram Sundial TGOD Flora’s Global Growth Potential. SOURCE: Company filings and presentations (August 2020) OF CURRENT CONTRACTED CAPACITY < 50%
24 FLORA GROWTH S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L Flora Growth IPO Q2 Q3 Q4 Avaria JV LOI Kalaya Brand Vessel Acquisition Completed Tropi Distribution Agreement Cosechemos Farm GACP Certification Vessel Acquisition LOI Hoshi International EU Investment & Distribution Tonino Lamborghini License Agreement Stardog Launch at Macy’s M A Y J U L Y N O V E M B E R J U L Y O C T O B E R A U G U S T A U G U S T N O V E M B E R D E C E M B E R 2021 Execution Timeline.
25 FLORA GROWTH S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L NASDAQ IPO Flora Growth successfully listed on the NASDAQ exchange at the high-end of the range at US $5.00 under the ticker FLGC. Currently, Flora Growth pre-IPO investors are exercising their warrants, with over US$12M cash received from exercised warrants 1 Capital structure as of November 23, 2021 2 Financial position as of June 30, 2021 3 4M warrants from the Regulation A+ offering have been exercised since June 30, 2021. Financial numbers are estimated, unaudited, and are subject to change. Capital Structure.1 Shares Outstanding Options & Warrants Fully-Diluted Shares Outstanding 64.3 M 13.9 M 78.2 M Healthy balance sheet with minimal debt. All values are shown in USD ($). Financial Position $ 0.4M $ 32.1M $ 40.7M $ 18.8M Long-term debt 2 Financing gross proceeds Potential cash upon exercise of warrants 3 Cash balance 2 IPO & CAPITAL STRUCTURE
Thank You. e: info@floragrowth.com
RkJQdWJsaXNoZXIy NDMyMDk=